Form 4: Fate Therapeutics Director Robert Epstein Granted Stock Options

Director Robert Epstein received 40,000 stock options in Fate Therapeutics (FATE) on June 7, 2024, as part of the company's non-employee director compensation policy.

Summary

• Robert S. Epstein, a director of Fate Therapeutics Inc. (FATE), was granted 40,000 stock options on June 7, 2024.
• The options were granted under the Issuer's Amended and Restated Non-Employee Director Compensation Policy.
• The exercise price of the options is $3.68.
• The options will vest on the earlier of June 7, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on June 7, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, indicating stability and alignment of interests. It's a neutral positive.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the Board of Directors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize and retain board members.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing Fate Therapeutics' director compensation to companies like CRISPR Therapeutics, Editas Medicine, or Intellia Therapeutics would provide a more comprehensive understanding of its relative competitiveness.
• Industry benchmarks for director compensation often consider factors such as meeting attendance, committee participation, and overall contribution to the company's strategic direction.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and strategic decision-making.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates